The research team, led by Lars Jacob Stovner of the Norwegian University of Science and Technology together with Ann Kristin Skrindo Knudsen, Lars Lien, Henrik Peersen, and Nils Erik Gilhus, extracted and summed GBD 2023 estimates for more than two dozen conditions, from Alzheimer’s disease and stroke to anxiety, depression, migraine, epilepsy, and addiction. Because the GBD framework has no single “brain disorders” category, the authors combined the individual diagnoses themselves, drawing on data from the Norwegian Cause of Death Registry, patient registries, and epidemiological surveys processed through GBD’s Bayesian meta-regression tool, DisMod-AT. The scale of the data effort is considerable: GBD 2023 drew on more than 100,000 data sources worldwide to generate internally consistent estimates of prevalence, incidence, and mortality for every age group, sex, and location.

The headline numbers reveal a critical asymmetry. Brain disorders were responsible for 30.77 percent of all years lived with disability (YLDs) but only 22.31 percent of all years of life lost (YLLs). In other words, these are primarily conditions people live with rather than die from, which makes them especially consequential from a socioeconomic standpoint. Mental disorders were the single largest contributor to disability, accounting for 17.56 percent of all YLDs, with anxiety disorders alone responsible for 7.35 percent. Headache disorders, dominated by migraine, contributed another 4.91 percent of all YLDs, affecting half the population in any given year. When it comes to mortality, neurological disorders dominate, chiefly because of Alzheimer’s disease and dementia, which alone accounted for 5.47 percent of all years of life lost.

The study is also the first to track how the total burden of brain disorders has shifted over time in a single country. Comparing age-standardized rates from 1990 to 2023, the researchers found a tale of two very different trajectories. On the positive side, the burden of stroke fell dramatically, with DALY rates down 65 percent over the 34-year period. This decline reflects a genuine reduction in incidence of 52 percent, alongside a 71 percent drop in mortality, driven by falling smoking rates, better control of blood pressure and cholesterol, improved diabetes management, faster acute stroke treatment, and more targeted rehabilitation. Alcohol use disorder prevalence fell 43 percent, and meningitis, once a feared killer, saw its DALY rate collapse by 89 percent thanks to vaccination and antimicrobial therapy. There were even modest, though statistically uncertain, reductions in the prevalence and burden of Alzheimer’s disease and dementia, a trend that mirrors observations elsewhere in the world and is plausibly linked to improving cerebrovascular health across generations.

Against these successes stand several deeply worrying counter-trends. The most dramatic is Parkinson’s disease, for which age-standardized prevalence rose 271 percent and incidence rose 115 percent over the study period, producing a 43 percent increase in DALY rates and an extraordinary 263 percent increase in years lived with disability. The authors note that better survival and improved diagnosis may explain part of this rise, since mortality increased far less than prevalence, but they cannot fully account for the steep increase in incidence itself. Possible contributors under investigation include environmental toxicants and even the decline of smoking in industrialized countries, a protective factor in Parkinson’s. Identifying the preventable causes of this rise, the researchers argue, should be a high scientific priority.

Mental disorders show no such improvement and, in aggregate, grew substantially. Overall mental disorder prevalence rose 29 percent, driven mainly by anxiety disorders (up 57 percent), depressive disorders (up 26 percent), and eating disorders (up 18 percent). Anxiety disorders alone saw DALY rates climb 58 percent, making them the single largest level-3 brain disorder contributor to overall disease burden in Norway at 3.79 percent of all DALYs. None of the major mental disorders showed improvement over three decades, and the authors point to shifting diagnostic practices, increased awareness, and the documented rise in mental health problems among young girls as likely contributing factors. Similar trends have been reported in the United Kingdom, suggesting the pattern is not unique to Norway. Compounding the concern, drug use disorders went in the opposite direction to alcohol, with prevalence up 23 percent and mortality from drug use soaring 97 percent, a trend the authors link partly to the increasing availability of potent synthetic opioids and poly-substance abuse.

The methodology behind these estimates deserves attention, both for its power and its limitations. GBD quantifies health loss by multiplying disease prevalence by disability weights derived from community surveys of tens of thousands of people across many countries, scaled from zero to one. Years of life lost are calculated against the highest observed life expectancy globally, ensuring that no population is penalized for biology alone. Crucially, the GBD framework corrects for comorbidity in a multiplicative rather than additive fashion, so summing individual conditions to estimate the total brain disorder burden does not inflate the result. Yet the authors are candid that many Norwegian figures rest on extrapolations from neighboring and epidemiologically similar countries, and that residual bias from changing diagnostic definitions cannot be excluded. Some categories, notably autism spectrum disorder and central nervous system cancers, carry uncertainty intervals so wide that no firm trend conclusions can be drawn, and neurotrauma had to be excluded from the total burden entirely because GBD reports injuries by cause rather than anatomical site, meaning the reported figures are minimum estimates.

The socioeconomic implications extend well beyond healthcare budgets. Many of the most common brain disorders, including ADHD, migraine, epilepsy, multiple sclerosis, schizophrenia, and depression, strike in childhood, adolescence, or early adulthood, precisely the years when people build careers, relationships, and families. Early-onset conditions reduce workforce participation, generating costs through disability pensions, absenteeism, and reduced productivity at work, while their cumulative effects ripple through later life outcomes including marriage, careers, and child-rearing. Conditions that appear later in life, such as dementia, Parkinson’s disease, and stroke, impose a different but equally heavy load: intensive caregiving demands on relatives and mounting pressure on nursing home capacity. With Norway’s population continuing to age, the total number of stroke and dementia patients will likely remain high even as age-specific rates decline.

The message for policymakers is clear and double-edged. Where prevention and treatment have been effective, the data show measurable, decades-long improvements, as stroke and meningitis demonstrate. But for anxiety, depression, and headache disorders, three of the most burdensome conditions in the entire analysis, thirty years have delivered essentially no progress, and for Parkinson’s disease and drug use disorders the situation is actively deteriorating. The GBD study identifies few modifiable risk factors for mental disorders, underscoring how much basic research remains to be done. The authors urge continued monitoring of brain health through future GBD iterations, arguing that only systematic measurement can evaluate the real-world impact of new and often very costly treatments, pinpoint emerging threats before they become crises, and direct scarce research and healthcare resources to where they will save the most healthy years of life. As Norway’s experience shows, the brain is both the greatest single source of health loss in a modern welfare state and, until now, one of its most fragmented and neglected policy priorities.

Subject of Research: The national burden of neurological, mental, and substance use disorders in Norway and their trends from 1990 to 2023 using Global Burden of Disease Study 2023 data.

Article Title: The burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023

Article References: Stovner, L. J., Skrindo Knudsen, A. K., Lien, L., Peersen, H., & Gilhus, N. E. (2026). The burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023. The Lancet Regional Health – Europe, 70, Article 101857. https://doi.org/10.1016/j.lanepe.2026.101857

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101857

Keywords: brain disorders, disease burden, DALYs, Norway, Global Burden of Disease, mental health, neurological disorders, Parkinson's disease, stroke, anxiety disorders, substance use, disability

The sheer scale of the health loss attributed to headache disorders is staggering. In 2023 alone, these conditions accounted for an age-standardized rate of 541.9 years lived with disability (YLDs) per 100,000 people, firmly placing headaches as the sixth leading cause of disability globally. The metric of YLDs, integral to this study, encapsulates the time people endure debilitating symptoms that impair daily function and quality of life, offering a quantifiable measure of the disease impact beyond mere prevalence.

A striking feature of the data is the pronounced disparity between sexes. Women suffer more than double the headache-related health loss compared to men, with a YLD rate of 739.9 versus 346.1 per 100,000, respectively. This pronounced sex-based discrepancy is consistent across all age groups, with females enduring longer and more frequent bouts of headaches. The pathophysiological or hormonal underpinnings of this sex difference remain an active area of research, emphasizing the imperative for sex-specific preventive and therapeutic strategies in headache management.

Though tension-type headaches are nearly twice as common as migraines, the latter dominates the disability landscape. Migraines alone account for nearly 90% of all headache-attributed YLDs, underscoring their substantially greater severity and disabling potential. This paradox illustrates that the frequency of a headache disorder does not linearly correlate with its impact on daily function. Migraines, characterized by intense unilateral pulsing pain often accompanied by nausea, photophobia, and phonophobia, exact an immense toll on affected individuals and societies alike.

Geographically, the highest burdens of migraine-related disability are concentrated primarily in North Africa and the Middle Eastern regions, closely followed by economically affluent areas such as Europe and North America. These findings reflect complex interaction between environmental, genetic, and socioeconomic factors influencing headache epidemiology. Despite regional variability, the global footprint remains significant, pointing to universal challenges in diagnosis, treatment accessibility, and effective management.

One of the most critical revelations of the study relates to medication-overuse headache (MOH), a condition precipitated by excessive consumption of analgesics, often in attempts to manage persistent headaches. MOH exacerbates the overall headache burden disproportionally, with over one-fifth of all headache-related disability attributed to this preventable cause. The pathogenesis involves neuroadaptive changes induced by repeated pharmacologic exposure, leading to a paradoxical increase in headache frequency and severity, underscoring the necessity for cautious and educated use of pain medications.

Specifically, medication overuse contributes 22.6% to migraine-related disability in men and 14.1% in women, while it accounts for over 56% to 59% of tension-type headache-related disability across both sexes. This suggests that beyond primary headache pathophysiology, secondary headache disorders induced by treatment misuse amplify the health impact, posing substantial challenges for clinical management and patient education.

Despite the profound burden and persistence of headache disorders over the last thirty years, the study illuminates a disconcerting plateau in their prevalence and related disability, suggesting that root causes and effective preventive measures remain inadequately addressed worldwide. Such stagnation reflects systemic gaps in healthcare delivery, research prioritization, and public health awareness, magnifying the urgency for targeted interventions.

Innovative public health approaches focusing on integrating headache services into primary care platforms, particularly in low- and middle-income countries, could revolutionize the current landscape. Improved access to affordable, evidence-based treatments alongside comprehensive education on medication use can substantially reduce disability and enhance productivity on a population level. Implementing health systems strengthening to prioritize headache disorders is now a clearly delineated global health imperative.

Furthermore, the study highlights the critical need for sex-specific research endeavors and gender-sensitive clinical protocols that consider the differential burden on women. Hormonal influences, psychosocial factors, and potential genetic susceptibilities warrant deeper exploration to tailor effective therapies and preventive strategies, potentially mitigating the disproportionately high headache-related disability observed among women.

Despite effective pharmacologic and non-pharmacologic interventions being available, such as triptans, CGRP antagonists, behavioral therapies, and lifestyle modifications, access to these therapies remains uneven globally. Barriers include scarcity of trained headache specialists, stigma, economic constraints, and lack of public awareness, which perpetuate unmet needs and continued disability.

In conclusion, this extensive epidemiological analysis delineates headache disorders as a colossal and chronic global health challenge that has remained unresolved for decades. Its findings unequivocally underscore the necessity for multifaceted strategies encompassing improved healthcare delivery, rigorous research, public education, and judicious medication use. Addressing these challenges with coordinated international efforts could dramatically alleviate the global headache burden and vastly improve quality of life for billions.

Subject of Research: Global burden and epidemiology of headache disorders, including migraine, tension-type headache, and medication-overuse headache.

Article Title: Headache Disorders Affect Nearly One-Third of the Global Population and Rank Sixth in Health Loss, Reveals Global Burden of Disease 2023 Study.

News Publication Date: 12-Nov-2025

Web References:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00402-8/fulltext

Keywords: Headaches, Pain, Migraines, Neurological disorders, Chronic pain, Disease incidence, Health care, Health disparity, Health care delivery, Human health, Public health, Pharmaceuticals, Medications, Analgesics, Antiinflammatory drugs, Drug sensitivity